Myxedema coma is an infrequent but potentially fatal complication of hypothyroidism. We present a rare case of previously undiagnosed hypothyroidism presenting in cardiogenic shock from pericardial tamponade and depressed myocardial contractility in myxedema coma. Here, we focus on cardiovascular complications associated with the condition.
including antinuclear antibodies, antineutrophil cytoplasm antibodies, rheumatoid factors, hepatitis antibodies, and extractable nuclear antigen antibodies-all tests were negative with the exception of an isolated positive U1 ribonucleoprotein antibody.
Our patient's hospital stay spanned almost 3 months, most of which was in the intensive care unit, and she suff ered several complications of myxedema coma. After draining the pericardial fl uid, a drain remained in place for almost 5 days with minimal additional fl uid formation once thyroid replacement was initiated. Her cardiac function improved and she remained hemodynamically independent after replacement of thyroid hormone. She suff ered from respiratory failure that required a tracheostomy with a slow prolonged weaning course off the ventilator. She also developed embolic ischemic strokes, required a percutaneous endoscopic gastrostomy (PEG) tube, and was treated with antibiotics and antifungals through her recovery. She was eventually decannulated, her PEG tube was removed, and plans were made for her to be transferred to a long-term care facility.
DISCUSSION
Th yroid hormone plays a ubiquitous role in the body's metabolic processes, and hypothyroidism is the clinical manifestation of a defi ciency in thyroid hormone. Th is process aff ects all organ systems. Th e extent of clinical impact depends on the degree of hormone defi ciency. Myxedema coma is a rare life-threatening complication of hypothyroidism. It either occurs as a natural progression of the disease or is precipitated by an infection or other events such as drug overdose (in particular, sedative drugs like opioids), myocardial infarction, or cold exposure in the setting of previously existing chronic hypothyroidism (1) . It most commonly aff ects elderly women. Hypothyroidism is present in about 6% of the population to varying degrees, but myxedema coma is seen in only 0.1% of this subgroup of patients (1) . Early and widespread use of thyroid-stimulating hormone assays has led to a progressive decline in the prevalence of this condition (2) . It still retains a high mortality rate of almost 40% despite aggressive treatment (1) .
Key to diagnosis is understanding that myxedema coma is diagnosed clinically based on presentation and is supported by other laboratory values. As expected, the clinical manifestations are not restricted to one organ system. Th e cardiovascular complications of this condition are varied and well known. Sinus bradycardia, low voltage complexes, bundle branch blocks, complete heart blocks, and nonspecifi c ST-T changes in the electrocardiogram have been recorded in myxedema crisis (1) . Hypothyroid patients have dia-stolic hypertension even in the setting of decreased cardiac output. Th is is thought to be due to the development of an imbalance in the alpha and beta adrenergic receptors with long-term hypothyroidism (3) . Th e number of beta-adrenergic receptors is reduced, usually with preservation of alpha-adrenergic receptors and circulating catecholamines, causing beta/alpha-adrenergic imbalance, diastolic hypertension, reduced total blood volume, and other manifestations (3). In severe hypothyroidism, bradycardia and decreased myocardial contractility can alone result in hypotension (1) .
A pericardial eff usion is a notable fi nding that is seen uncommonly in hypothyroidism but more frequently in patients with 4). Rarely, pericardial eff usion progresses to cardiac tamponade and impairs ventricular function. Case reports over the years have described myxedema coma-associated pericardial eff usions causing cardiac tamponade (5, 6) .
Th e backbone of treatment for myxedema coma is thyroid replacement. Aggressive supportive therapy and management of comorbidities is also critical for survival. Th yroid hormone is usually replaced intravenously as it is hypothesized that gut edema from a myxedematous state may not allow adequate and prompt absorption (7) . Reports have suggested that replacement of thyroid hormone by nasogastric tube may also be suffi cient (1) . Parenteral administration of thyroid hormones presents the risk of arrhythmia from rapidly increasing serum concentrations and is an accepted risk of necessary therapy. Debate still exists about the type of thyroid replacement and dosage. A combination of T3 and T4 thyroxine is usually preferred, as deiodinase conversion of T4 to T3 is thought to be compromised in these settings (2) . Daily doses of T4 in the range of 1.6 mcg/kg are recommended after a loading dose of 200 mcg. T3 is usually administered in doses of 5 to 10 mg loading, followed by doses of 2.5 to 10 mcg every 8 hours given the short half-life of T3. Administering T3 does not remain without risk, as its more immediate action is even more likely to cause arrhythmia, particularly in patients with previous heart disease (8) . As seen with this patient, the complications of myxedema are typically reversible with hormone replacement. Supplemental steroids are administered unless proven to not be adrenal insuffi cient. Supportive therapy for comorbid infections and adequate fl uid resuscitation are critical. 
